Access cutting-edge cutaneous t cell lymphoma treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.
Access cutaneous t cell lymphoma specialists in Boston at no cost
This study follows strict safety protocols and ethical guidelines
All study-related cutaneous t cell lymphoma treatment provided free
This is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL). PTX-100 will be administered by IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles, then 21 day cycle thereafter. Subjects will be treated or followed up, if subjects discontinue treatment, for up to 18 months.
Sponsor: Prescient Therapeutics, Ltd.
Check if you qualify for this cutaneous t cell lymphoma clinical trial in Boston, MA
If you're searching for cutaneous t cell lymphoma treatment options in Boston, MA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced cutaneous t cell lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.